Skip to main content
48°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xilio Therapeutics Inc
(NQ:
XLO
)
0.9100
-0.0100 (-1.09%)
Streaming Delayed Price
Updated: 9:30 AM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xilio Therapeutics Inc
< Previous
1
2
3
4
Next >
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 08, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
November 07, 2024
Via
Benzinga
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
November 07, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
November 07, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 30, 2024
Via
Benzinga
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
October 30, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
October 04, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 28, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q2 2024
August 08, 2024
XLO stock results show that Xilio Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
August 08, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
June 13, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024
May 14, 2024
XLO stock results show that Xilio Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
May 14, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
April 09, 2024
Via
Benzinga
XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023
April 01, 2024
XLO stock results show that Xilio Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
April 01, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 01, 2024
Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expected fourth-quarter financial results.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
April 01, 2024
Via
Benzinga
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
April 01, 2024
Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 01, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
April 01, 2024
It's time to start the trading week with a dive into the biggest pre-market stock movers worth watching on Monday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
March 29, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
March 29, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
March 29, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
March 28, 2024
Via
Benzinga
Crude Oil Surges Over 2%; MSC Industrial Shares Fall After Q2 Results
March 28, 2024
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 15 points on Thursday. The Dow traded up 0.06% to 39,785.29 while the NASDAQ fell 0.13% to 16,383.85. The...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 28, 2024
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of...
Via
Benzinga
Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why
March 28, 2024
Xilio Therapeutics soars with exclusive license pact with Gilead Sciences to advance XTX301, a Phase 1 tumor-activated IL-12 program. $43.5 million upfront, $604 million potential payments, and tiered...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
March 28, 2024
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.